EUDA Health Holdings Ltd Trading Halted Due to Volatility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Should l Buy EUDA?
EUDA Health Holdings Ltd trading halted, volatility trading pause
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EUDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EUDA
About EUDA
EUDA Health Holdings Limited is a health technology company. The Company operates a southeast Asian digital healthcare ecosystem. Its unified artificial intelligence platform assesses patients' medical history, triages conditions, digitally connects patients with clinicians, and predicts optimal treatment outcomes. Its holistic approach supports patients throughout all stages of care, including wellness and prevention, urgent care and emergencies, pre-existing conditions, and aftercare services. Its medical urgent care services provide healthcare assistance and medical evacuation to individual and corporate clients. Its property management service covers the management of properties, such as condominiums and shopping malls. Its services include e-triage, GP consult, e-medical certificates, and medical prescriptions. Its EUDA platform provides medical services from primary to post-surgery care and ongoing preventive healthcare for clients, regardless of the level of healthcare required.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
EUDA Health Holdings Secures Shenzhen R&D Project Approval
- Project Approval: EUDA Health Holdings' subsidiary Shenzhen Inno has received approval under the 2025 Shenzhen Key Industry R&D Program, expected to secure approximately $434,688 in funding to advance the key technology development of TCR-T therapy, thereby reinforcing the company's position in cellular immunotherapy.
- Technological Innovation: The project will utilize AI-driven high-throughput screening technologies to develop HLA-restricted epitopes targeting multiple tumor types, aiming to address challenges such as tumor heterogeneity and immune resistance, thus enhancing the efficacy and durability of therapies.
- Clinical Collaboration: Shenzhen Inno is collaborating with Shenzhen People's Hospital to conduct clinical studies evaluating the safety and efficacy of the new therapies while developing standardized manufacturing processes to support the rollout of advanced cellular therapies, thereby strengthening market competitiveness.
- Strategic Alignment: The approval of this project aligns closely with EUDA's strategic objectives, indicating the company's commitment to expanding access to advanced treatment modalities through its commercial channels, further promoting the delivery of science-driven healthcare solutions.
See More
EUDA Health Faces Nasdaq Compliance Challenge
- Compliance Notification: EUDA Health Holdings received a written notice from Nasdaq on April 23, 2026, indicating that it failed to maintain the Minimum Market Value of Listed Securities (MVLS) of $35 million for 32 consecutive business days, triggering a compliance clock and highlighting potential listing risks for the company.
- Compliance Deadline: The company has 180 days, until October 20, 2026, to achieve a market value of at least $35 million for 10 consecutive trading days within this period to avoid a delisting notice from Nasdaq, increasing operational pressure on the company.
- Market Performance: Despite the compliance challenges, EUDA's stock rose by 21.09% to $12.86 on Monday, but fell by 3.50% in overnight trading, indicating market uncertainty regarding its future performance.
- Business Context: EUDA Health Holdings focuses on non-invasive and preventive healthcare services across Singapore, Malaysia, and China, aiming to meet the health needs of a rapidly aging population; however, compliance issues may impact its market expansion and investor confidence.
See More
EUDA Health Price Target Cut to $2.75 by Analyst
- Price Target Adjustment: Analyst William Gregozeski has lowered EUDA Health's price target from $6 to $2.75 while maintaining a Buy rating, reflecting a cautious outlook on future sales performance.
- Sales Forecast Reduction: The expected sales of Helixe bottles in 2026 have been revised down from 105,000 to 50,000, resulting in a revenue estimate drop from $43.05 million to $27.23 million, indicating a significant weakening in market demand.
- Dilutive Impact: The analyst highlights that the issuance of 12.5 million shares in late February has a dilutive effect on EPS estimates, which may undermine investor confidence in the company's profitability.
- Capital Dynamics: EUDA Health's capital moves in 2026 include repurchasing and canceling the Streeterville warrant, raising $3.75 million to improve its financial position, demonstrating proactive measures in adjusting its capital structure.
See More
EUDA Health Holdings Fully Repurchases Warrant
- Warrant Repurchase: EUDA Health Holdings fully repurchased and canceled the warrant issued to Streeterville Capital for a total of $125,000 on February 27, 2026, eliminating the potential issuance of 2 million new ordinary shares and enhancing the stability of the company's capital structure.
- Strategic Focus: As a non-invasive healthcare provider focused on Singapore, Malaysia, and China, EUDA aims to become a market leader in the rapidly growing longevity sector, addressing the healthcare needs of over 1.8 billion people, particularly the 30% of the population that is aging rapidly.
- Market Positioning: By offering innovative, accessible, and science-backed health solutions, EUDA is actively transforming regional healthcare from reactive treatment to proactive, longevity-focused care, further solidifying its market position in the Asia-Pacific region.
- Business Diversification: In addition to healthcare services, EUDA operates a property management business in Singapore, demonstrating its strategic approach to diversification, which aims to enhance overall business resilience through multiple revenue streams.
See More
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
- Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
- Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
- Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
- Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
See More
EUDA Health Holdings Lowers Warrant Exercise Price to $4
- Warrant Amendment: EUDA has amended its agreement with Streeterville Capital to reduce the warrant exercise price from $6 to $4 per share, which is expected to enhance investor willingness to exercise the warrants, thereby improving the company's liquidity.
- Forced Exercise Condition Adjustment: The minimum closing price required for a forced exercise has been lowered from $7.50 to $6.00, which may encourage more investors to exercise their warrants during market fluctuations, further optimizing the company's capital structure.
- Strengthened Market Positioning: EUDA focuses on the non-invasive healthcare market in Singapore, Malaysia, and China, aiming to address the healthcare needs of over 1.8 billion people, positioning itself strategically in the rapidly growing longevity sector amid accelerating demographic shifts.
- Business Diversification: In addition to healthcare, EUDA operates a property management business in Singapore, showcasing its capability to diversify across multiple sectors, aiming to enhance overall market competitiveness through varied business operations.
See More
EUDA Health Holdings Secures Shenzhen R&D Project Approval
- Project Approval: EUDA Health Holdings' subsidiary Shenzhen Inno has received approval under the 2025 Shenzhen Key Industry R&D Program, expected to secure approximately $434,688 in funding to advance the key technology development of TCR-T therapy, thereby reinforcing the company's position in cellular immunotherapy.
- Technological Innovation: The project will utilize AI-driven high-throughput screening technologies to develop HLA-restricted epitopes targeting multiple tumor types, aiming to address challenges such as tumor heterogeneity and immune resistance, thus enhancing the efficacy and durability of therapies.
- Clinical Collaboration: Shenzhen Inno is collaborating with Shenzhen People's Hospital to conduct clinical studies evaluating the safety and efficacy of the new therapies while developing standardized manufacturing processes to support the rollout of advanced cellular therapies, thereby strengthening market competitiveness.
- Strategic Alignment: The approval of this project aligns closely with EUDA's strategic objectives, indicating the company's commitment to expanding access to advanced treatment modalities through its commercial channels, further promoting the delivery of science-driven healthcare solutions.
See More
EUDA Health Faces Nasdaq Compliance Challenge
- Compliance Notification: EUDA Health Holdings received a written notice from Nasdaq on April 23, 2026, indicating that it failed to maintain the Minimum Market Value of Listed Securities (MVLS) of $35 million for 32 consecutive business days, triggering a compliance clock and highlighting potential listing risks for the company.
- Compliance Deadline: The company has 180 days, until October 20, 2026, to achieve a market value of at least $35 million for 10 consecutive trading days within this period to avoid a delisting notice from Nasdaq, increasing operational pressure on the company.
- Market Performance: Despite the compliance challenges, EUDA's stock rose by 21.09% to $12.86 on Monday, but fell by 3.50% in overnight trading, indicating market uncertainty regarding its future performance.
- Business Context: EUDA Health Holdings focuses on non-invasive and preventive healthcare services across Singapore, Malaysia, and China, aiming to meet the health needs of a rapidly aging population; however, compliance issues may impact its market expansion and investor confidence.
See More
EUDA Health Price Target Cut to $2.75 by Analyst
- Price Target Adjustment: Analyst William Gregozeski has lowered EUDA Health's price target from $6 to $2.75 while maintaining a Buy rating, reflecting a cautious outlook on future sales performance.
- Sales Forecast Reduction: The expected sales of Helixe bottles in 2026 have been revised down from 105,000 to 50,000, resulting in a revenue estimate drop from $43.05 million to $27.23 million, indicating a significant weakening in market demand.
- Dilutive Impact: The analyst highlights that the issuance of 12.5 million shares in late February has a dilutive effect on EPS estimates, which may undermine investor confidence in the company's profitability.
- Capital Dynamics: EUDA Health's capital moves in 2026 include repurchasing and canceling the Streeterville warrant, raising $3.75 million to improve its financial position, demonstrating proactive measures in adjusting its capital structure.
See More
EUDA Health Holdings Fully Repurchases Warrant
- Warrant Repurchase: EUDA Health Holdings fully repurchased and canceled the warrant issued to Streeterville Capital for a total of $125,000 on February 27, 2026, eliminating the potential issuance of 2 million new ordinary shares and enhancing the stability of the company's capital structure.
- Strategic Focus: As a non-invasive healthcare provider focused on Singapore, Malaysia, and China, EUDA aims to become a market leader in the rapidly growing longevity sector, addressing the healthcare needs of over 1.8 billion people, particularly the 30% of the population that is aging rapidly.
- Market Positioning: By offering innovative, accessible, and science-backed health solutions, EUDA is actively transforming regional healthcare from reactive treatment to proactive, longevity-focused care, further solidifying its market position in the Asia-Pacific region.
- Business Diversification: In addition to healthcare services, EUDA operates a property management business in Singapore, demonstrating its strategic approach to diversification, which aims to enhance overall business resilience through multiple revenue streams.
See More
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
- Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
- Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
- Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
- Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
See More
EUDA Health Holdings Lowers Warrant Exercise Price to $4
- Warrant Amendment: EUDA has amended its agreement with Streeterville Capital to reduce the warrant exercise price from $6 to $4 per share, which is expected to enhance investor willingness to exercise the warrants, thereby improving the company's liquidity.
- Forced Exercise Condition Adjustment: The minimum closing price required for a forced exercise has been lowered from $7.50 to $6.00, which may encourage more investors to exercise their warrants during market fluctuations, further optimizing the company's capital structure.
- Strengthened Market Positioning: EUDA focuses on the non-invasive healthcare market in Singapore, Malaysia, and China, aiming to address the healthcare needs of over 1.8 billion people, positioning itself strategically in the rapidly growing longevity sector amid accelerating demographic shifts.
- Business Diversification: In addition to healthcare, EUDA operates a property management business in Singapore, showcasing its capability to diversify across multiple sectors, aiming to enhance overall market competitiveness through varied business operations.
See More
